Fred Campbell's Biography

Fred Campbell, Scientific Director, NanoVation Therapeutics UK

Fred obtained his PhD from the University of Leeds, UK and has 15 years’ experience in the design and evaluation of lipid-based nanomedicines. During this time, he has advanced our fundamental understanding of how lipid-based nanoparticles are recognized and processed within the body and has developed innovative ways to exploit or evade these dominant interactions. Recipient of a Marie Curie fellowship, he has published >25 peer-reviewed articles in high impact journals.

LNP 2.0+: Gene Medicine Beyond Covid

Tuesday, 14 November 2023 at 09:30

Add to Calendar ▼2023-11-14 09:30:002023-11-14 10:30:00Europe/LondonLNP 2.0+: Gene Medicine Beyond CovidExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

mRNA vaccines against SARS-Cov2 have emphatically shown lipid nanoparticles (LNPs) can deliver safe and effective gene therapies in humans, can be developed at unprecedented speed, manufactured at scale and all at reasonable cost. A genetic healthcare revolution is now upon us. How quickly these new, diverse and life changing treatments come to market, however, will require many outstanding challenges to be met (both scientifically and commercially). Here, I will briefly outline NTx’s strategic and scientific efforts to accelerate the development of new LNP-based gene medicines and democratize healthcare for all.

Add to Calendar ▼2023-11-13 00:00:002023-11-14 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023Extracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors